{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"ORR will be calculated for all treated patients for each disease cohort. The corresponding 95% two-sided confidence interval will be derived.","groups":[{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG000","title":"Treatment (Ixazomib Citrate, Rituximab) for CLL/SLL"},{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG001","title":"Treatment (Ixazomib Citrate, Rituximab) for FL"},{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG002","title":"Treatment (Ixazomib Citrate, Rituximab) for MZL"},{"description":"Patients receive ixazomib citrate orally (PO) on days 1, 8 ,15, and 22. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon completion of 6 cycles of ixazomib citrate therapy, patients also receive rituximab intravenously (IV) once weekly for 4 doses total, followed by ixazomib citrate alone, until disease progression or unacceptable toxicity.\n\nIxazomib Citrate: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nRituximab: Given IV","id":"OG003","title":"Treatment (Ixazomib Citrate, Rituximab) for MCL"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Overall Response Rate (ORR) (Complete Response [CR] + Partial Response [PR]) in Patients With Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL)","type":"PRIMARY","unitOfMeasure":"Participants"}